摘要
目的观察缬沙坦/氨氯地平复方制剂治疗原发性高血压的疗效及对动脉血管分泌内皮素-1(ET-1)水平的影响。方法选取82例初治原发性高血压患者,随机分为缬沙坦/氨氯地平复方制剂组(A组)42例与氨氯地平单药组(B组)40例,另选取同期血压正常的健康体检者40例作为对照组(C组)。A组给予缬沙坦/氨氯地平片(80/5mg),B组给予氨氯地平片5mg,均1次/d,共12周。于治疗第2、4、8、12周测量患者静息血压、降压有效率、ET-1水平以及不良反应发生率。结果治疗结束时,A、B两组降压有效率差异无统计学意义(P>0.05),A组降压速度及血压稳定性优于B组(P<0.05),且A组血浆ET-1水平低于B组(P<0.05),并恢复至正常水平,与C组比较,差异无统计学意义(P>0.05),而B组ET-1水平仍高于C组,差异有统计学意义(P<0.05)。A组不良反应率低于B组(P<0.05)。结论缬沙坦/氨氯地平复方制剂能有效地控制原发性高血压患者的血压,保护血管内皮功能,降低药物不良反应发生率。
Objective To observe the efficacy of valsartan/amlodipine compound preparation in the treatment of essential hypertension and the effect on endothelin-1（ET-1）levels secreted by arteries.Methods A total of 82 previously untreated patients with essential hypertension were randomly divided into valsartan/amlodipine compound preparation group and amlodipine monotherapy group,40 cases for each.The former was treated with valsartan/amlodipine tablets（80/5mg）per day,and the later was administered by amlodipine for 5 mg per day,both were treated for 12 weeks.The resting blood pressure,antihypertension effective rates and ET-1levels of all patients in 2,4,8,12 weeks were measured.Results The difference of antihypertension effective rates between two groups were not statistically significant（P〉 0.05）.Blood pressure decrease rate and blood pressure stability in compound preparation group were better than those of amlodipine monotherapy group（P〈0.05）,meanwhile the ET-1level in the former group was significantly lower than that in the later（P〈0.05）,and even restored to normal levels.Adverse reaction rates in compound preparation group was obviously lower than in amlodipine monotherapy group（P〈0.05）.Conclusion Valsartan/amlodipine compound preparation can effectively control the blood pressure in patients with essential hypertension and protect the endothelial function,and it is relatively safe in clinical use.
出处
《成都医学院学报》
CAS
2015年第3期298-301,共4页
Journal of Chengdu Medical College
基金
中国高校医学期刊临床专项资金项目(No:11522742)
